
Rapport Therapeutics, Inc. (NASDAQ:RAPP) stock traded higher on Monday, with a session volume of 3.20 million compared to the average volume of 179.3 thousand, according to data from Benzinga Pro.
On Monday, the company revealed data from the Phase 2a trial of RAP-219 (RAP-219-FOS-201) in patients with drug-resistant focal onset seizures.